-
June 17, 2013
The pricing and reimbursement conditions for InterMune's Esbriet was approved in Italy.
-
June 17, 2013
The rejection of Elan management's proposed transactions ought to accelerate the sale of the company.
-
June 13, 2013
PDL BioPharma announced that it expects to receive second quarter 2013 royalty revenues of around $143 million.
-
June 10, 2013
Elan's Board of Directors again rejected Royalty Pharma's offer to acquire all its shares.
-
May 21, 2013
Elan seems to be set on wasting the Tysabri windfall instead of returning it to shareholders
-
February 11, 2013
Biogen Idec (BIIB) and partner, Swedish Orphan Biovitrum recently presented encouraging data on their hemophilia ...
-
February 07, 2013
Elan Corporation (ELN) reported earnings of 15 cents per share for the fourth quarter of 2012 compared to the ...
-
February 04, 2013
Spectrum Pharmaceuticals (SPPI) recently announced that it has regained development and commercial rights for ...
-
February 04, 2013
Elan Corporation plc (ELN) recently decided to sell its remaining 7.8 million ordinary shares in Alkermes plc (ALKS) ...
-
January 28, 2013
Biogen Idec (BIIB) reported fourth quarter earnings per share of $1.40, missing the Zacks Consensus Estimate of ...
-
December 27, 2012
Elan Corporation, plc (ELN), a neuroscience-based biotechnology company, recently completed the separation of a ...
-
December 13, 2012
Eli Lilly (LLY) recently provided an update on its plans for its Alzheimer's disease candidate, solanezumab. The ...
-
December 07, 2012
PDL BioPharma Inc. (PDLI) recently announced that it expects to generate fourth quarter 2012 royalty revenues of $86 ...
-
November 28, 2012
Elan Corporation (ELN) recently initiated a phase II study on ELND005 (Study AG201) for the treatment of ...
-
November 16, 2012
We are reverting to a Neutral recommendation on Alkermes plc (ALKS) from Outperform as we believe that the stock is ...
-
November 07, 2012
PDL BioPharma Inc. (PDLI) posted third-quarter earnings of 32 cents per share, in line with the Zacks Consensus ...
-
November 05, 2012
Alkermes plc (ALKS) reported earnings of 3 cents per share (including depreciation and stock-based compensation ...
-
November 02, 2012
Acorda Therapeutics Inc. (ACOR) reported third quarter earnings (including share-based compensation charges but ...
-
October 25, 2012
Biogen Idec (BIIB) reported third quarter earnings per share of $1.90, well above the Zacks Consensus Estimate of ...
-
October 25, 2012
Elan Corporation's (ELN) loss of 5 cents per share (excluding special items) for the second quarter of 2012 was ...
